Cerus Q3 revenue up 10% to $46.3M; narrows FY product revenue guidance to $160-162M

CERUS CORP

2022-Q3 EPS reported -$0.17

Net loss improved to $8.5M ($0.05/sh) from $12.4M ($0.07/sh) in Q3 2021.
Product gross margin expanded to 55.4% from 51.3% YoY; adjusted EBITDA loss narrowed to $2.7M.
Cash and investments at $103.8M; net cash used in ops $2.1M vs $6.6M prior year.
Guidance narrowed to $160-162M product revenue from $160-165M, citing FX headwinds.
Awarded $9.1M DoD contract for LyoCryo; Health Canada approved 7-day platelet shelf life.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CERUS CORP reported third quarter ended September 30, 2022 results: revenue $46.3 million, net income $8.5 million, EPS $0.05 per basic and diluted share. Guidance reaffirmed.

Period: third quarter ended September 30, 2022
Revenue: $46.3 million
Net income: $8.5 million
EPS: $0.05 per basic and diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Cerus Corporation Announces Third Quarter Financial Results Total Revenue of $46.3 Million Grew 10% YoY in the Third Quarter Product Revenue of $39.6 Million Grew 10% YoY in the Third Quarter despite 6% FX headwind CONCORD, CA, November 3, 2022 - Cerus Corporation

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

CERUS CORP filing history →

Source: SEC EDGAR

accession 0001193125-22-276881

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.